With the appearance of imatinib and the consequent decline of allografts for CML, the myelodysplastic syndrome (MDS) has recently become much more interesting to readers of Bone Marrow Transplantation. This book, edited by Peter Greenberg is therefore timely. It contains a comprehensive survey of the condition. Peter Greenberg was responsible for the prognostic classification of MDS, and his chapter on this is authoritative and complete. Richard Brunning was deeply involved in the development of the WHO morphological classification of MDS, and his chapter is similarly authoritative. The chapter on pathogenetic mechanisms underlying the condition is sound and orthodox, but where so much is still a mystery, one could, perhaps, have wished for a more speculative approach. Cytogenetic and molecular mechanisms are expertly handled and in the centre of the book are some beautiful photomicrographs. Indeed, one would like to have seen more of them.
The section on immune mechanisms concentrates on treatment with ATG, which is certainly important, but there is much more that is of interest. It is when we get to treatment that the textbook format shows its weakness. The hot news in MDS treatment at the moment is the astonishing success of lenalidomide in 5q minus syndrome and the equally unexpected success of 5-azacytidine in patients with deletions of chromosome 7. Although both these drugs are mentioned, the delay inherent in publishing a multi-author book means that neither is given the attention it deserves. For the most part, references date from 2002 or 2003; almost all of the thirteen 2004 references were provided by the editor himself in his two chapters. This is not a criticism of the scholarship, merely a consequence of the format.
Nevertheless this is an excellent starter book for those who want to understand MDS. It is well written and well produced, not intimidatingly large, and certainly carries authority. I shall keep it on my shelves alongside similar volumes from John Bennett (2002), Raza and Mundle (2001) and Mufti and Galton (1992) . The speed at which the field is advancing means that they will soon be joined by others.
